CD274 and non-small cell lung carcinoma: Therefore, the development of antagonist against PD-1 or PD-L1 has emerged as a valuable therapeutic strategy to enhance the activity of T cells against tumoral cells, especially for melanoma, non-small cell lung cancer, renal cell carcinoma or Hodgkin lymphoma, among others, where durable responses were observed in 20–40% of patients [30,31].